Get the Stockscreener App
2.42
0.00%
0.00
After Hours:
2.42
Palisade Bio Inc stock is traded at $2.42, with a volume of 21,441.
It is up +0.00% in the last 24 hours and down -31.44% over the past month.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
See More
Previous Close:
$2.42
Open:
$2.45
24h Volume:
21,441
Relative Volume:
0.27
Market Cap:
$3.70M
Revenue:
-
Net Income/Loss:
$-12.30M
P/E Ratio:
-0.3763
EPS:
-6.4313
Net Cash Flow:
$-11.13M
1W Performance:
-0.82%
1M Performance:
-31.44%
6M Performance:
-50.71%
1Y Performance:
-72.33%
1-Day Range:
$2.38
$2.48
1-Week Range:
$2.35
$2.6999
52-Week Range:
$2.18
$22.35
Palisade Bio Inc Stock (PALI) Company Profile
Name
Palisade Bio Inc
Sector
Industry
Phone
(858) 704-4900
Address
7750 EL CAMINO REAL, SUITE 5200, CARLSBAD
Compare PALI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PALI
Palisade Bio Inc
|
2.42 | 3.70M | 0 | -12.30M | -11.13M | -6.4313 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Palisade Bio Inc Stock (PALI) Latest News
Brookline Capital Management Estimates Palisade Bio FY2024 Earnings - Defense World
Palisade Bio to Present Preclinical Results for PALI-2108 - GlobeNewswire
Palisade Bio's PALI-2108 Shows Promise in Preclinical IBD Treatment Study | PALI Stock News - StockTitan
Brookline Capital Initiates Coverage of Palisade Bio (PALI) with Buy Recommendation - MSN
ARMISTICE CAPITAL, LLC Acquires Shares in Palisade Bio Inc - GuruFocus.com
Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) Summit - The Manila Times
Contrasting Palisade Bio (NASDAQ:PALI) & Anavex Life Sciences (NASDAQ:AVXL) - Defense World
Palisade Bio Inc (PALI) Quarterly 10-Q Report - Quartzy
Palisade Bio Reports Third Quarter 2024 Financial Results - GlobeNewswire
Palisade Bio Advances UC Drug Trial: Key Phase 1 Milestones & Patent Wins Boost Pipeline | PALI Stock News - StockTitan
Palisade Bio initiates phase 1 study of new UC drug - Investing.com
Palisade Bio initiates phase 1 study of new UC drug By Investing.com - Investing.com Australia
Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC) - The Manila Times
Intelligent Bio Solutions Reports Fiscal 2025 First Quarter Financial Results and Operational Highlights - The Manila Times
Palisade Bio Announces First Subject Dosed in Phase 1 - GlobeNewswire
Palisade Bio Launches Phase 1 Trial for Novel Ulcerative Colitis Drug PALI-2108 | PALI Stock News - StockTitan
Palisade Bio (NASDAQ:PALI) and Allogene Therapeutics (NASDAQ:ALLO) Critical Survey - Defense World
Palisade Bio advances novel IBD treatment PALI-2108 - Investing.com
Palisade Bio advances novel IBD treatment PALI-2108 By Investing.com - Investing.com UK
HYCU® Recognized as CRN 2024 Product of the Year Finalist - The Manila Times
Palisade Bio Announces Positive Data from Two Ex Vivo - GlobeNewswire
Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis - StockTitan
PALI stock touches 52-week low at $3.09 amid market fluctuations - Investing.com
Alto Neuroscience’s depression drug trial fails at phase 2 - BioPharma-Reporter.com
Alto Neuroscience’s Depression Trial Failure Sends Shares Into Downward Spiral - MedCity News
Palisade Bio Announces Abstract Accepted for Presentation - GlobeNewswire
Sutro Biopharma (NASDAQ:STRO) & Palisade Bio (NASDAQ:PALI) Head-To-Head Contrast - Defense World
Meta Platforms (NASDAQ:META) Shares Up 0.6% Following Analyst Upgrade - Defense World
Palisade Bio receives Health Canada nod for UC drug trial By Investing.com - Investing.com Australia
Palisade Bio receives Health Canada nod for UC drug trial - Investing.com
Palisade Bio Cleared by Health Canada to Commence Phase 1 - GlobeNewswire
Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC) - Yahoo Finance
Palisade Bio to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC - The Manila Times
Pre-market Movers: GANX, TFFP, AKYA, CLDI... - RTTNews
Palisade Bio, Inc. (NASDAQ:PALI) Shares Sold by Armistice Capital LLC - Defense World
Palisade Bio inks new deal with CEO Finley; terms disclosed By Investing.com - Investing.com Canada
Palisade Bio inks new deal with CEO Finley; terms disclosed - Investing.com India
Palisade Bio CEO Finley’s Revised Employment and Compensation Deal - TipRanks
Palisade submits CTA for PDE4 inhibitor prodrug for ulcerative colitis - BioWorld Online
PALI stock touches 52-week low at $3.3 amid market fluctuations - Investing.com UK
PALIPalisade Bio, Inc. Latest Stock News & Market Updates - StockTitan
Palisade Bio Provides Update on Progress Toward Launch of - GlobeNewswire
Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis - StockTitan
Klea Holding Evaluates Generous Takeover Offer - TipRanks
The growth track for Kura Oncology Inc (KURA) has changed recently - SETE News
Potential Price Increase for Kulicke & Soffa Industries, Inc. (KLIC) After Recent Insider Activity - Knox Daily
Big Changes At Disney Animation: Jennifer Lee Steps Down And Jared Bush Steps In - mxdwn.com
116,268 Shares in Proficient Auto Logistics, Inc. (NASDAQ:PAL) Purchased by First Eagle Investment Management LLC - MarketBeat
Angelina Jolie overwhelmed by ‘beautiful feeling’ of motherhood - FemaleFirst
Anitra (AMEX:AZTR) Stock Quotes, Forecast and News Summary - Benzinga
Palisade Bio (NASDAQ:PALI) Stock Quotes, Forecast and News Summary - Benzinga
Palisade Bio Inc Stock (PALI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Palisade Bio Inc Stock (PALI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Wei Binxian | Director |
Nov 21 '24 |
Option Exercise |
0.00 |
388 |
0 |
855 |
| Wei Binxian | Director |
Jun 11 '24 |
Option Exercise |
0.00 |
465 |
0 |
467 |
| Williams Donald Allen | Director |
Jun 11 '24 |
Option Exercise |
0.00 |
340 |
0 |
340 |
| Jones Mitchell Lawrence | Chief Medical Officer |
May 28 '24 |
Option Exercise |
0.00 |
4,290 |
0 |
4,313 |
| Finley John David | CEO, CFO, Director |
May 28 '24 |
Option Exercise |
0.00 |
7,068 |
0 |
14,079 |
| Williams Donald Allen | Director |
May 28 '24 |
Buy |
4.86 |
1,000 |
4,863 |
1,000 |
| Finley John David | CEO, CFO, Director |
May 24 '24 |
Buy |
4.81 |
1,000 |
4,810 |
8,437 |
| Jones Mitchell Lawrence | CEO, CFO, Director |
May 06 '24 |
Option Exercise |
0.00 |
460 |
0 |
880 |
| Finley John David | CEO, CFO, Director |
May 06 '24 |
Option Exercise |
0.00 |
443 |
0 |
6,832 |
| Finley John David | CEO, CFO, Director |
Mar 11 '24 |
Option Exercise |
0.00 |
5,558 |
0 |
96,849 |
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):